These results suggest that incorporation of PD1 blockade to the NK cell expansion protocol may have considerable value in improving NK cell-based therapy for MM and other malignancies, and that the therapeutic effects of in vitro expanded NK with PD1 blockage deserve a clinical trial in MM and other malignancies. Here, PDCD1 is linked to Miyoshi myopathy.